icad (NASDAQ:ICAD), Inc. is a Nashua, New Hampshire–based medical technology company specializing in digital oncology solutions and treatment planning software. With a focus on early cancer detection and therapy workflow optimization, iCAD develops and markets advanced imaging and radiation treatment systems designed to improve clinical outcomes and streamline patient care. The company’s product suite leverages artificial intelligence, advanced algorithms and proprietary image-analysis tools to assist radiologists, oncologists and cancer centers in delivering personalized, efficient care.
Among iCAD’s flagship offerings is the ProFound AI® platform, an FDA-cleared deep-learning solution for mammography and digital breast tomosynthesis that enhances lesion detection and reduces reading times. In the therapeutic realm, iCAD markets the Xoft® Axxent® Electronic Brachytherapy System, an intraoperative radiation therapy (IORT) device that delivers targeted radiation at the time of surgery, minimizing exposure to healthy tissues. Complementing these core products, the company offers a suite of oncology workflow and data-management tools designed to integrate with existing health-system infrastructures.
Founded in 1984 as a digital design and imaging specialist, iCAD has evolved through strategic acquisitions and in-house innovation to become a recognized leader in AI-driven cancer detection technologies. The company maintains a direct sales presence in North America while partnering with distributors across Europe, Asia and other key markets to broaden its global footprint. iCAD’s research and development teams collaborate with leading academic institutions and clinical partners to validate and refine new applications for its imaging and treatment platforms.
Under the leadership of President and CEO Brent D. Shafer, iCAD continues to expand its product pipeline and pursue regulatory clearances worldwide. By combining advanced software, data analytics and targeted radiation solutions, the company aims to support healthcare providers in delivering earlier diagnoses, more precise treatments and improved patient outcomes in the fight against cancer.
